D-dimer and pulmonary arterial hypertension in systemic sclerosis

Journal of the Medical Association of Thailand

Volumn 90, Issue 10, 2007, Pages 2024-2029

  Kiatchoosakun, Songsak ^a,b   Ungkasekvinai, Wichai ^a   Wonvipaporn, Chaiyasit ^a   Tatsanavivat, Pyatat ^a   Foocharoen, Chingching ^a   Suwannaroj, Siraphop ^a   Nanagara, Ratanavadee ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

D dimer; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

D DIMER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART RIGHT VENTRICLE PRESSURE; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TURBIDIMETRY;

ADULT; AGED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEALTH STATUS INDICATORS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ARTERY; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 35848967010     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-800.
2. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-93.
3. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 453-9.
4. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-50.
5. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-9.
6. Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coagul Fibrinolysis 1998; 9: 107-17.
7. Farber HW, Loscalzo J. Prothrombotic mechanisms in primary pulmonary hypertension. J Lab Clin Med 1999; 134: 561-6.
8. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82: 841-7.
9. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-7.
10. Wagenvoort CA, Mulder PG. Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication? Chest 1993; 103: 844-9.
11. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110: 710-7.
12. Denton CP, Black CM. Targeted therapy comes of age in scleroderma. Trends Immunol 2005; 26: 596-602.
13. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369: 587-96.
14. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol 1998; 59: 65-73.
15. Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview. Thromb Haemost 1994; 71: 1-6.
16. Rowbotham BJ, Carroll P, Whitaker AN, Bunce IH, Cobcroft RG, Elms MJ, et al. Measurement of crosslinked fibrin derivatives - use in the diagnosis of venous thrombosis. Thromb Haemost 1987; 57: 59-61.
17. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
18. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-7S.
19. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124: 2098-104.
20. Silver RM. Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am 1996; 22: 825-40.
21. Wagenvoort CA, Wagenvoot N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 1163-84.
22. Lopes AA, Maeda NY. Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Chest 1998; 114: 1276-82.
23. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 487-92.
24. Shitrit D, Bendayan D, Bar-Gil-Shitrit A, Huerta M, Rudensky B, Fink G, et al. Significance of a plasma D-dimer test in patients with primary pulmonary hypertension. Chest 2002; 122: 1674-8.
25. Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med 2003; 35: 605-13.
26. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991; 69: 209-15.
27. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001; 116: 417-25.
28. Maeda M, Kachi H, Mori S. Plasma levels of molecular markers of blood coagulation and fibrinolysis in progressive systemic sclerosis (PSS). J Dermatol Sci 1996; 11: 223-7.
29. Cerinic MM, Valentini G, Sorano GG, D'Angelo S, Cuomo G, Fenu L, et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003; 32: 285-95.
30. Lippi G, Volpe A, Caramaschi P, Salvagno GL, Montagnana M, Guidi GC. Plasma D-dimer concentration in patients with systemic sclerosis. Thromb J 2006; 4: 2-4.
31. Prisco D, Antonucci E, Marcucci R, Pepe G. D-dimer in the year 2000: current data and new perspectives. Ann Ital Med Int 2000; 15: 267-72.
32. Arkel YS, Paidas MJ, Ku DH. The use of coagulation activation markers (soluble fibrin polymer, TpP, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagul Fibrinolysis 2002; 13: 199-205.
33. Lippi G, Mengoni A, Manzato F. Plasma D-dimer in the diagnosis of deep vein thrombosis. JAMA 1998; 280: 1828-9.
34. Dunn KL, Wolf JP, Dorfman DM, Fitzpatrick P, Baker JL, Goldhaber SZ. Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. J Am Coll Cardiol 2002; 40: 1475-8.
35. Currie PJ, Seward JB, Chan KL, Fyfe DA, Hagler DJ, Mair DD, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985; 6: 750-6.